SS Innovations Reports Strong 2025 Growth with 105.7% Revenue Increase and Expansion of Surgical Robotics Market Share

SS Innovations International, Inc. reported unaudited financial results for the three and twelve months ended December 31, 2025, demonstrating substantial growth in its surgical robotics business. For the full year 2025, revenue increased 105.7% to $42.5 million from $20.6 million in 2024, while gross profit rose 131.2% to $19.5 million. The company's net loss improved to $12.1 million compared to $19.2 million in the prior year.

Installations of the SSi Mantra surgical robotic system totaled 103 in 2025, representing a 119.1% increase from 47 installations in 2024. As of December 31, 2025, the cumulative installed base reached 168 systems across ten countries, with cumulative surgeries totaling 7,885 procedures. This includes 120 telesurgeries, 390 cardiac procedures, and 121 pediatric surgeries, demonstrating the system's versatility across multiple surgical specialties.

Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, highlighted the company's market expansion achievements, stating they gained significant share of the surgical robotics market in India and expanded into new global geographies. The company also progressed along regulatory pathways required for entering the United States and European Union markets. On December 5, 2025, SS Innovations submitted a 510(k) premarket notification to the United States Food and Drug Administration for the SSi Mantra surgical robotic system, covering multiple indications including general, urological, colorectal, gynecological and cardiac surgeries. The company anticipates FDA review completion by mid-2026 and is pursuing European Union CE marking certification this year.

The company continued to pioneer robotic telesurgery, achieving multiple milestones including the first telesurgery performed with the SSi Mantra Tele Surgeon Console on November 6, 2025. Subsequent developments included the announcement on January 6, 2026 of five new 5-millimeter surgical instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery. Financial stability was enhanced through a private placement completed on March 9, 2026, generating approximately $18.6 million in gross proceeds to support growth initiatives. The offering included significant insider participation, with directors and executive officers purchasing approximately $5.2 million worth of shares at an average price of $4.00 per share.

Fourth quarter 2025 results showed continued momentum with revenue increasing 79.1% to $14.5 million from $8.1 million in the same period of 2024. SSi Mantra installations totaled 40 in the quarter, up 81.8% from 22 installations in the fourth quarter of 2024. The company's cash position stood at $3.2 million as of December 31, 2025, with no long-term debt. The uplisting of shares to Nasdaq has enhanced market awareness and expanded the investor audience according to company leadership. More information is available through the company's investor relations resources at https://tinyurl.com/ssiinewsroom.

SS Innovations' growth strategy focuses on deploying the SSi Mantra in existing and new markets while investing in system enhancements. The company aims to lead the Indian market, penetrate underserved global geographies, and prepare for entry into the United States and European Union. The SSi Mantra system features modular robotic arms, an open-faced ergonomic surgeon command center, large 3D 4K monitors, and supports over 40 different types of robotic endo-surgical instruments. The system has been clinically validated in India in more than 100 different types of surgical procedures, establishing its versatility and reliability in diverse clinical settings.